
Alnylam (ALNY) · Biotechnology
Alnylam Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Alnylam cut its 2026 TTR revenue outlook as growth in second-line AMVUTTRA demand normalized after early pent-up demand, even as ATTR-CM diagnosis and treatment keep growing.
AMVUTTRA, the only product approved across the full spectrum of ATTR amyloidosis, drove TTR revenue past $1 billion in a quarter for the first time. U.S. demand growth was more than double the prior quarter's, and international demand rose in both hATTR-PN and ATTR-CM. Alnylam launched AMVUTTRA in Spain, started two Phase 2 studies (ALN-6400 and mivelsiran) and began a Phase 1 obesity trial of ALN-6222.
Management says it will keep investing heavily to make AMVUTTRA a foundational ATTR-CM therapy, expand it internationally through a China partnership with BeOne Medicines, and push the pipeline toward readouts in the second half. It is also building AI into discovery, diagnosis and commercial analytics. The main tension is that the early ATTR-CM launch benefited from pent-up demand, so growth in second-line use has settled at a lower level than expected.
Key numbers
- Total revenues · GAAP
- $1.3B
- Income from operations · GAAP
- $231.4M
- Income from operations (non-GAAP) · non-GAAP
- $318.1M
- Net income · GAAP
- $164.5M
- Diluted EPS · GAAP
- $1.21
- Diluted EPS (non-GAAP) · non-GAAP
- $1.84
up 67% from a year ago
vs. a loss of $(16,199) a year ago
up 233% from a year ago
vs. a loss of $(72,228) a year ago
vs. $(0.55) a year ago
vs. $0.28 a year ago
| Segment or metric | Value | Change |
|---|---|---|
| AMVUTTRA net product revenues | $1.0B | up 106% from a year ago |
| ONPATTRO net product revenues | 18.5M | down 65% from a year ago |
| Total TTR net product revenues | $1,030 million | 89% growth compared to Q2 2025 |
| GIVLAARI net product revenues | 89.8M | up 11% from a year ago |
| OXLUMO net product revenues | 52.1M | up 11% from a year ago |
| Royalty revenue | 71.7M | up 79% from a year ago |
Where each number comes from
- Total revenues: “Total revenues | $1,290,948 | $773,689 | 67% GAAP Income (loss) from operations | $231,441 | $(16,199) | ** Non-GAAP Income from operations | $318,066 | $95,481 | 233%”
- Income from operations: “GAAP Income (loss) from operations | $231,441 | $(16,199) | ** Non-GAAP Income from operations | $318,066 | $95,481 | 233%”
- Income from operations (non-GAAP): “Non-GAAP Income from operations | $318,066 | $95,481 | 233% GAAP Net income (loss) | $164,494 | $(72,228) | ** Non-GAAP Net income | $251,801”
- Net income: “GAAP Net income (loss) | $164,494 | $(72,228) | ** Non-GAAP Net income | $251,801 | $38,171 | * GAAP Net income (loss) per common share — basic | $1.23”
- Diluted EPS: “GAAP Net income (loss) per common share — diluted | $1.21 | $(0.55) | ** Non-GAAP Net income per common share — basic | $1.88 | $0.29 | * Non-GAAP Net income per common share — diluted | $1.84”
- Diluted EPS (non-GAAP): “Non-GAAP Net income per common share — basic | $1.88 | $0.29 | * Non-GAAP Net income per common share — diluted | $1.84 | $0.28 | * * Indicates the percentage change”
- AMVUTTRA net product revenues: “Net product revenues: AMVUTTRA | $1,011,762 | $491,953 | 106% | 106% ONPATTRO | 18,461 | 52,538 | (65)% | (65)% Total TTR net product revenues | 1,030,223”
- ONPATTRO net product revenues: “ONPATTRO | 18,461 | 52,538 | (65)% | (65)% Total TTR net product revenues | 1,030,223 | 544,491 | 89% | 89% GIVLAARI | 89,764”
- Total TTR net product revenues: “together representing $1,030 million in total TTR net product revenues and 89% total TTR growth compared to Q2 2025.”
- GIVLAARI net product revenues: “GIVLAARI | 89,764 | 80,849 | 11% | 10% OXLUMO | 52,122 | 46,872 | 11% | 9% Total Rare net product revenues | 141,886”
- OXLUMO net product revenues: “OXLUMO | 52,122 | 46,872 | 11% | 9% Total Rare net product revenues | 141,886 | 127,721 | 11% | 10% Total net product revenues | 1,172,109”
- Royalty revenue: “Royalty revenue | 71,674 | 39,981 | 79% | 79% Total revenues | $1,290,948 | $773,689 | 67% | 67% * Change at constant exchange rates”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.3B | +66.9% | — |
| Operating income | $231.4M | — | — |
| Net income | $164.5M | — | −20.1% |
| Diluted EPS | $1.21 | — | — |
| Operating margin | 17.9% | +20.0 pts | — |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Total TTR net product revenues | full-year 2026 | $4,200 million - $4,500 million |
| Total Rare net product revenues | full-year 2026 | $500 million - $600 million |
| Total net product revenues | full-year 2026 | $4,700 million - $5,100 million |
| Net revenues from collaborations and royalties | full-year 2026 | $575 million - $625 million |
Key takeaways
Second-line ATTR-CM demand normalized after pent-up launch
Alnylam says growth in second-line AMVUTTRA demand moderated in early 2026, after an early launch that benefited from patients waiting for a new option. This drove the cut to TTR guidance.
U.S. demand growth accelerated despite the guidance cut
U.S. TTR revenues rose $106 million over Q1, driven by a $129 million increase in demand. That demand growth was more than double Q1's growth over Q4 2025.
AI is being built into discovery and diagnosis
Alnylam partnered with Inceptive on RNAi discovery, with a California health system on AI-enabled ATTR-CM screening (DETECT-ATTR), and expanded its Komodo Health partnership. Together these target earlier diagnosis and sharper commercial targeting.
BeOne deal opens China for AMVUTTRA
Alnylam entered an exclusive agreement with BeOne Medicines to commercialize AMVUTTRA in mainland China and Macao, subject to marketing authorization. A Spain launch also extends the product's global reach.
Pipeline widens across new disease areas
Alnylam started Phase 2 trials of ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer's, plus a Phase 1 obesity trial. Regeneron's cemdisiran filing for gMG has a November 2026 FDA target date under Priority Review.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $593.2M * |
| Q1 2025 | $594.2M |
| Q2 2025 | $773.7M |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.1B * |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.5B |
Data
| Q1 2025 | -$0.14 |
| Q2 2025 | -$0.55 |
| Q3 2025 | $2.14 |
| Q2 2026 | $1.21 |
| Q3 2026 | $15.72 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -17.7% |
| Q1 2025 | 3.0% |
| Q2 2025 | -2.1% |
| Q3 2025 | 29.5% |
| Q4 2025 | 12.0% |
| Q2 2026 | 17.9% |
| Q3 2026 | 23.7% |
Data
| Q4 2024 | -$103.8M |
| Q1 2025 | -$127.3M |
| Q2 2025 | $113.5M |
| Q3 2025 | $284.7M |
| Q4 2025 | $194.4M |
| Q3 2026 | $271.2M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
Why did Alnylam lower its 2026 TTR guidance?
Growth in second-line AMVUTTRA demand in the U.S. moderated in early 2026 to what the company now believes is a normalized level, after an early launch period that benefited from pent-up demand from patients waiting for a new therapy.
Is demand for AMVUTTRA still growing?
Yes. U.S. TTR revenues rose $106 million over Q1, driven by a $129 million demand increase that was more than double Q1's demand growth, and international demand rose in both hATTR-PN and ATTR-CM.
How is Alnylam expanding AMVUTTRA's reach?
It launched in Spain and agreed an exclusive deal with BeOne Medicines to commercialize it in mainland China and Macao, pending marketing authorization. It also began the DemonsTTRate real-world study, expected to enroll more than 2,000 ATTR-CM patients.
How is Alnylam using AI?
It partnered with Inceptive to apply foundation models to RNAi discovery, supported a California health system study of AI-enabled cardiac amyloid screening, and expanded its use of Komodo Health's Marmot analytics platform.
What pipeline events are coming?
In the second half of 2026 Alnylam expects data on ALN-6400 in HHT and ALN-2232 in obesity, and will present ALN-HTT02 Huntington's Phase 1 results on October 23, 2026. The FDA target action date for cemdisiran in gMG is November 2026.
Documents
SEC filing